Blinding and bias in randomized controlled trials: when to measure the effectiveness of blinding

Dev Med Child Neurol. 2020 Feb;62(2):260. doi: 10.1111/dmcn.14369. Epub 2019 Sep 30.

Authors

Lisa Copeland¹, Priya Edwards¹, Leanne Sakzewski², Megan Thorley¹, Megan Kentish¹, Robert S Ware³, Roslyn N Boyd²

Affiliations

¹ Queensland Paediatric Rehabilitation Service, Queensland Children's Hospital, South Brisbane, Queensland, Australia.
² Queensland Cerebral Palsy and Rehabilitation Research Centre, The University of Queensland, Brisbane, Queensland, Australia.
³ Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia.

PMID: 31571206
DOI: 10.1111/dmcn.14369

No abstract available

Publication types

Letter
Comment

MeSH terms

Bias
Botulinum Toxins, Type A*
Cerebral Palsy*
Child
Double-Blind Method
Humans
Movement Disorders*

Substances

Botulinum Toxins, Type A